Shimose, S.; Iwamoto, H.; Tanaka, M.; Niizeki, T.; Kajiwara, M.; Itano, S.; Moriyama, E.; Shirono, T.; Noda, Y.; Kamachi, N.;
et al. Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. Cancers 2022, 14, 4284.
https://doi.org/10.3390/cancers14174284
AMA Style
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Kajiwara M, Itano S, Moriyama E, Shirono T, Noda Y, Kamachi N,
et al. Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. Cancers. 2022; 14(17):4284.
https://doi.org/10.3390/cancers14174284
Chicago/Turabian Style
Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, Takashi Niizeki, Masahiko Kajiwara, Satoshi Itano, Etsuko Moriyama, Tomotake Shirono, Yu Noda, Naoki Kamachi,
and et al. 2022. "Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study" Cancers 14, no. 17: 4284.
https://doi.org/10.3390/cancers14174284
APA Style
Shimose, S., Iwamoto, H., Tanaka, M., Niizeki, T., Kajiwara, M., Itano, S., Moriyama, E., Shirono, T., Noda, Y., Kamachi, N., Nakano, M., Kuromatsu, R., Koga, H., & Kawaguchi, T.
(2022). Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. Cancers, 14(17), 4284.
https://doi.org/10.3390/cancers14174284
